

## Immunophenotyping for lymphoid and myeloid malignancies (full clinical details required)

### General information

Cell surface markers appropriate to diagnostic information provided (see sections on Acute and Chronic leukaemia panels).

The relevant tests required will be specified for each individual case.

**Specimen transport:** Samples should be received within 24 hours of collection

**Repeat frequency:** Post treatment monitoring, suspected relapse and MRD

**Special precautions:** Samples should be maintained at room temperature

### Laboratory information

**Reporting units:** Percentage of the population of cells of interest

**Volume and sample type:** 5ml EDTA blood or bone marrow

**Method:** Flow Cytometry

**Turnaround time (calendar days from sample receipt to authorised result):** Median - 2, 95th percentile – 7

**Participation in EQA Scheme:** UK NEQAS Leukaemia Immunophenotyping Part 1 and 2

### Clinical information

**Indications for the test:**

- Suspected lymphoid/myeloid malignancy
- To confirm relapse
- To confirm remission

**Factors affecting the test:** Specimens should be ideally <24 hours old and never more than 48 hours old

(Last updated February 2021)